Pure Global
NCT06285890

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

M.D. Anderson Cancer Center·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
HC-7366
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Aug 31, 2024
End date
Dec 31, 2029
Enrollment
18 participants
Primary outcome

Safety and adverse events (AEs)

Summary

To find a recommended dose of HC-7366 that can be given in combination with azacitidine and
 venetoclax to patients with AML. The safety and effects of this drug combination will also be
 studied.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06285890
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06285890 through Pure Global AI's free database. This Phase 1 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.